$38.4 Million is the total value of Asymmetry Capital Management, L.P.'s 16 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 52.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XNPT | Buy | XENOPORT INC | $7,340,000 | +3.2% | 1,627,628 | +25.6% | 19.14% | +77.9% |
| LLY | New | ELI LILLY & CO | $4,709,000 | – | 65,400 | +100.0% | 12.28% | – |
| DGX | Sell | QUEST DIAGNOSTICS INC | $4,544,000 | -31.6% | 63,595 | -31.9% | 11.85% | +17.8% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $2,818,000 | +48.9% | 333,513 | +70.9% | 7.35% | +156.6% |
| NVRO | Sell | NEVRO CORP | $2,778,000 | -25.1% | 49,377 | -10.1% | 7.24% | +29.2% |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $2,499,000 | +8.0% | 63,188 | +54.5% | 6.52% | +86.2% |
| UNH | Sell | UNITEDHEALTH GROUP INC | $2,307,000 | -45.0% | 17,900 | -49.8% | 6.01% | -5.3% |
| TEVA | Sell | TEVA PHARMACEUTICAL-SP ADRadr | $2,209,000 | -55.3% | 41,286 | -45.2% | 5.76% | -22.9% |
| IPXL | Buy | IMPAX LABORATORIES INC | $1,987,000 | -9.6% | 62,050 | +20.6% | 5.18% | +55.8% |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $1,710,000 | -18.3% | 140,587 | +63.7% | 4.46% | +40.9% |
| New | BIO-RAD LABRATORIES | $1,647,000 | – | 12,050 | +100.0% | 4.29% | – | |
| EW | Sell | EDWARDS LIFESCIENCES CORP | $1,392,000 | -62.7% | 15,780 | -66.6% | 3.63% | -35.7% |
| CNC | Sell | CENTENE CORP | $730,000 | -87.1% | 11,850 | -86.2% | 1.90% | -77.8% |
| QDEL | New | QUIDEL CORP | $717,000 | – | 41,550 | +100.0% | 1.87% | – |
| OSUR | New | ORASURE TECHNOLOGIES INC | $500,000 | – | 69,200 | +100.0% | 1.30% | – |
| ANAC | Sell | ANACOR PHARMACEUTICALS INC | $473,000 | -73.1% | 8,850 | -43.2% | 1.23% | -53.7% |
| SGYPQ | Exit | SYNERGY PHARMACEUTICALS INC | $0 | – | -303,157 | -100.0% | -2.60% | – |
| PACB | Exit | PACIFIC BIOSCIENCES OF CALIF | $0 | – | -145,306 | -100.0% | -2.88% | – |
| ALKS | Exit | ALKERMES PLC | $0 | – | -29,350 | -100.0% | -3.52% | – |
| ACOR | Exit | ACORDA THERAPEUTICS INC | $0 | – | -145,509 | -100.0% | -9.41% | – |
| PTCT | Exit | PTC THERAPEUTICS INC | $0 | – | -237,100 | -100.0% | -11.62% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-04-21
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.